Radioembolization in the treatment of unresectable liver tumors: Experience across a range of primary cancers

Douglas Coldwell*, Bruno Sangro, Riad Salem, Harpreet Wasan, Andrew Kennedy

*Corresponding author for this work

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

Radioembolization is a proven treatment to slow disease progression and improve survival in patients with colorectal cancer liver metastases and hepatocellular carcinoma. Accumulating evidence supports its use in metastases from neuroendocrine tumors and breast cancer. Cancers with radiobiologic profiles similar to those of colorectal and breast cancer, including melanoma, lung cancer, and nodular cholangiocarcinoma, are being studied as candidates for radioembolization. This treatment modality has also been shown to downsize hepatic tumors for potentially curative ablation in patients with breast, pancreatic, and colorectal cancer. Radioembolization using either yttrium-90 ( 90Y)-labeled resin or glass microspheres represents a promising therapy for liver-only or liver-predominant tumors in patients with 1 or more variables, including adequate or sufficient functional liver reserve, good performance status, and absence of other significant comorbidities. Therapeutic efficacy and safety can be best achieved by use of careful dosimetric techniques and treatment planning. Radioembolization could be considered after progression of liver metastases during treatment hiatus, at an early therapeutic line in tumors that respond poorly to chemotherapy, or in treatment-refractory disease.

Original languageEnglish (US)
Pages (from-to)167-177
Number of pages11
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume35
Issue number2
DOIs
StatePublished - Apr 1 2012

Fingerprint

Liver
Neoplasms
Colorectal Neoplasms
Therapeutics
Breast Neoplasms
Neoplasm Metastasis
Planning Techniques
Yttrium
Neuroendocrine Tumors
Cholangiocarcinoma
Status Epilepticus
Liver Neoplasms
Pancreatic Neoplasms
Microspheres
Glass
Disease Progression
Comorbidity
Hepatocellular Carcinoma
Melanoma
Lung Neoplasms

Keywords

  • Breast
  • Cholangiocarcinoma
  • Melanoma
  • SIR.T.
  • Yttrium-90

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{e661b0d607464ef982265403f34935f0,
title = "Radioembolization in the treatment of unresectable liver tumors: Experience across a range of primary cancers",
abstract = "Radioembolization is a proven treatment to slow disease progression and improve survival in patients with colorectal cancer liver metastases and hepatocellular carcinoma. Accumulating evidence supports its use in metastases from neuroendocrine tumors and breast cancer. Cancers with radiobiologic profiles similar to those of colorectal and breast cancer, including melanoma, lung cancer, and nodular cholangiocarcinoma, are being studied as candidates for radioembolization. This treatment modality has also been shown to downsize hepatic tumors for potentially curative ablation in patients with breast, pancreatic, and colorectal cancer. Radioembolization using either yttrium-90 ( 90Y)-labeled resin or glass microspheres represents a promising therapy for liver-only or liver-predominant tumors in patients with 1 or more variables, including adequate or sufficient functional liver reserve, good performance status, and absence of other significant comorbidities. Therapeutic efficacy and safety can be best achieved by use of careful dosimetric techniques and treatment planning. Radioembolization could be considered after progression of liver metastases during treatment hiatus, at an early therapeutic line in tumors that respond poorly to chemotherapy, or in treatment-refractory disease.",
keywords = "Breast, Cholangiocarcinoma, Melanoma, SIR.T., Yttrium-90",
author = "Douglas Coldwell and Bruno Sangro and Riad Salem and Harpreet Wasan and Andrew Kennedy",
year = "2012",
month = "4",
day = "1",
doi = "10.1097/COC.0b013e3181f47923",
language = "English (US)",
volume = "35",
pages = "167--177",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Radioembolization in the treatment of unresectable liver tumors : Experience across a range of primary cancers. / Coldwell, Douglas; Sangro, Bruno; Salem, Riad; Wasan, Harpreet; Kennedy, Andrew.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 35, No. 2, 01.04.2012, p. 167-177.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Radioembolization in the treatment of unresectable liver tumors

T2 - Experience across a range of primary cancers

AU - Coldwell, Douglas

AU - Sangro, Bruno

AU - Salem, Riad

AU - Wasan, Harpreet

AU - Kennedy, Andrew

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Radioembolization is a proven treatment to slow disease progression and improve survival in patients with colorectal cancer liver metastases and hepatocellular carcinoma. Accumulating evidence supports its use in metastases from neuroendocrine tumors and breast cancer. Cancers with radiobiologic profiles similar to those of colorectal and breast cancer, including melanoma, lung cancer, and nodular cholangiocarcinoma, are being studied as candidates for radioembolization. This treatment modality has also been shown to downsize hepatic tumors for potentially curative ablation in patients with breast, pancreatic, and colorectal cancer. Radioembolization using either yttrium-90 ( 90Y)-labeled resin or glass microspheres represents a promising therapy for liver-only or liver-predominant tumors in patients with 1 or more variables, including adequate or sufficient functional liver reserve, good performance status, and absence of other significant comorbidities. Therapeutic efficacy and safety can be best achieved by use of careful dosimetric techniques and treatment planning. Radioembolization could be considered after progression of liver metastases during treatment hiatus, at an early therapeutic line in tumors that respond poorly to chemotherapy, or in treatment-refractory disease.

AB - Radioembolization is a proven treatment to slow disease progression and improve survival in patients with colorectal cancer liver metastases and hepatocellular carcinoma. Accumulating evidence supports its use in metastases from neuroendocrine tumors and breast cancer. Cancers with radiobiologic profiles similar to those of colorectal and breast cancer, including melanoma, lung cancer, and nodular cholangiocarcinoma, are being studied as candidates for radioembolization. This treatment modality has also been shown to downsize hepatic tumors for potentially curative ablation in patients with breast, pancreatic, and colorectal cancer. Radioembolization using either yttrium-90 ( 90Y)-labeled resin or glass microspheres represents a promising therapy for liver-only or liver-predominant tumors in patients with 1 or more variables, including adequate or sufficient functional liver reserve, good performance status, and absence of other significant comorbidities. Therapeutic efficacy and safety can be best achieved by use of careful dosimetric techniques and treatment planning. Radioembolization could be considered after progression of liver metastases during treatment hiatus, at an early therapeutic line in tumors that respond poorly to chemotherapy, or in treatment-refractory disease.

KW - Breast

KW - Cholangiocarcinoma

KW - Melanoma

KW - SIR.T.

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=84860645692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860645692&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181f47923

DO - 10.1097/COC.0b013e3181f47923

M3 - Review article

C2 - 21127414

AN - SCOPUS:84860645692

VL - 35

SP - 167

EP - 177

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -